Tim Smith

This new data indicated the strong safety profile and efficacy of CAL/BDP-cream using PAD technology for psoriasis patients, and could lead to better adherence and outcomes in real-world settings.

New data indicates associations between conditions for pregnant mothers and offspring, though a connection to offspring food allergy was not evident in this research.

This systematic review and meta-analysis demonstrated the potential effectiveness of JAK inhibitors for alopecia, though further trials are needed for long-term use.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

This new research highlighted the value of engaging Mohs surgery patients in shared decision-making to find the best pain control plan for their needs.

This new data demonstrated that hearing loss led to worse outcomes for older individuals, and fatigue assessments may be needed in the future to further capture fatigue’s multidimensionality.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

Both biologic-naïve and biologic-experience patients saw benefits in the BRIGHT study examining therapeutic response to brodalumab over the course of 1 year.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.

New data indicates that hospital culture must be considered when facilities make significant changes, especially when they concern institutional values.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

New research on patients with pemphigus highlighted the heavy mental burden on those with these conditions and the importance of screening for anxiety, depression, and quality of life.

New research into menopausal hormone therapy shows that even short term use can have downstream consequences for neurological health.

New research into the information needs of adults over 65 and their patient portal interactions points to the value of consumer-oriented health information technologies.

New data drawn from the EUSTAR database made clear several key insights into this subset of systemic sclerosis patients, with survival and skin manifestations being highlighted.

In this Q&A interview with physician assistant Renata Block, Block spoke on some of her thoughts about the recent SDPA conference and its presentations.

This interview featured a discussion with Dr. Mostaghimi, during which he described some of the latest treatments for alopecia, new policies and efforts for patients, and general conference takeaways.

In this interview, physician assistant Hope Cook described some of the major talking points from her conference talk titled ‘Healing PA Burnout.’

In this discussion with HCPLive, Dr. Markowitz spoke about some of the biggest takeaways from her conference presentation on skin cancer treatments.

In this interview, Dr. Noor spoke about the contents of his conference presentation regarding the tailoring of treatment plans to patients with skin of color.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

Describing the biggest takeaways from her talk ‘Diagnosis and Management of Blistering Disorders,’ Dr. Noe went in depth about treatment of blistering in patients.

This interview with Dr. Noe at the SDPA conference featured a discussion about her background and her presentation titled ‘Diagnosis and Management of Blistering Disorders.'

In another interview segment, Dr. Amin described some of the other biggest points from his conference talk on choosing the best route for psoriasis in patients.

In this interview segment, Dr. Amin described some of the major takeaways from his conference talk titled ‘Biological Bootcamp: How to Select the Best Biologics for Your Psoriasis Patient.’

In a conference presentation, Dr. Imadojemu discussed the topic of afro-textured hair and various hair and scalp disorders.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.